[Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders]

D V Kurkin,E I Morkovin,D A Bakulin,Yu V Gorbunova,O V Ivanova,E V Pavlova,V I Zvereva,M A Dzhavakhyan,I S Krysanov,Yu A Kolosov,A V Zaborovsky,A V Strygin,V I Petrov,P A Beliy,K Y Zaslavskaya,D V Maltsev,M O Skripka

DOI: https://doi.org/10.17116/jnevro202412405122

Abstract:Depression is a leading cause of disability and reduced work capacity worldwide. The monoamine theory of the pathogenesis of depression has remained dominant for many decades, however, drugs developed on its basis have limited efficacy. Exploring alternative mechanisms underlying this pathology could illuminate new avenues for pharmacological intervention. Targeting glutamatergic pathways in the CNS, particularly through modulation of NMDA and AMPA receptors, demonstrates promising results. This review presents some existing drugs with glutamatergic activity and novel developments based on it to enhance the efficacy of pharmacotherapy for depressive disorders.